We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Determination of Drug-Like Properties of a Novel Antileishmanial Compound: In vitro Absorption, Distribution, Metabolism, and Excretion Studies
News

Determination of Drug-Like Properties of a Novel Antileishmanial Compound: In vitro Absorption, Distribution, Metabolism, and Excretion Studies

Determination of Drug-Like Properties of a Novel Antileishmanial Compound: In vitro Absorption, Distribution, Metabolism, and Excretion Studies
News

Determination of Drug-Like Properties of a Novel Antileishmanial Compound: In vitro Absorption, Distribution, Metabolism, and Excretion Studies

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Determination of Drug-Like Properties of a Novel Antileishmanial Compound: In vitro Absorption, Distribution, Metabolism, and Excretion Studies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ABSTRACT

In drug discovery research, the compounds should not only to be potent and selective but also must possess acceptable pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME) to increase success rate in clinical studies.

MATERIALS AND METHODS: Experimental protocols were established and validated for stability (in PBS pH7.4, simulated gastric and intestinal fluid), solubility, permeability, distribution coefficient (Log D), plasma protein binding and metabolism by rat liver microsomes by using spectrophotometer or HPLC. Methods were considered valid if the results of the standard compounds matched with reported results or within acceptable range or with proper ranking (high-medium-low).

RESULTS: The compound was found to be stable (>95% remaining) in all stability studies and aqueous solubility was 299.7 +/- 6.42 muM. The parallel artificial membrane permeability assay (PAMPA) indicated its medium permeability (Log Pe = -5.53 +/- 0.01). The distribution coefficients (Log D) in octanol/PBS and cyclohexane/PBS systems were found to be 0.54 and -1.33, respectively. The plasma protein binding study by the equilibrium dialysis method was observed to be 78.82 +/- 0.13% while metabolism by Phase-I enzymes for 1 hour at 37 degrees C revealed that 36.07 +/- 4.15% of the compound remained after metabolism.

CONCLUSION: The methods were found to be very useful for day-to-day ADME studies. All the studies with the antileishmanial compound ascertained that the compound bears optimum pharmacokinetic properties to be used orally as a potential drug for the treatment of leishmaniasis.

The article is published in the Indian Journal of Pharmacology and free to access.

Advertisement